With this study we would like to obtain a DaTSCAN SPECT database with normal subjects.
Conditions
Interventions
Trade Name: DaTSCAN
Pharmaceutical Form:
Sponsors
Hospital Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Documented inform consent 2. Subjects aged 36 to 85 with a clinical evidence of no parkinsonian signs or symptoms (assess by UPDRS) and no evidence of any movement disorder. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Drugs that it is known that may interact with DaTSCAN. 2. Any medical condition that may interact with DaTSCAN or yodine pharmachocinetic (i.e. renal or liver failure) 3. Subject with hypersensitivity to yodine 4. Ocupational exposure to radiation higher than 15 mSv/year 5. Current Abuse of drugs or alcohol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To Obtain the normal distribution of striatal DAT uptake in a normal population.;Secondary Objective: 1.Characterize the different gammacameras that will be use in the study 2. To obtain a DaTSCAN normal database from normal subjects 3. To adequate the database to be use with other gammacameras and quantification programs;Primary end point(s): To obtain the striatal DaTSCAN uptake ratio in healthy subjects, based on DaTSCAN quantification. | — |
Countries
Spain
Outcome results
None listed